Study details
Enrolling now
Study to Find the Best Dose of CYAD-02 for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Celyad Oncology SA
NCT IDNCT04167696ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
27
Study length
about 15 years
Ages
18+
Locations
2 sites in FL, KS
What this study is about
Researchers are testing a treatment called CYAD-02 in people with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It aims to find the best dose of CYAD-02 that can be safely used. The trial will involve 27 patients who have not responded to other treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CYAD-02
- 2.Take ENDOXAN
- 3.Take Fludara
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology